PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
PTK787/ZK222584 is an orally active inhibitor of VEGF-R tyrosine kinases. Bevacizumab is an
intravenous humanized monoclonal antibody directed against vascular endothelial growth
factor. By binding to VEGF, bevacizumab blocks VEGF-A receptor binding. Due to the different
mechanisms of action and the non-overlapping toxicity profiles of the two agents, it is hoped
that a combination regimen incorporating both compounds will produce increased activity
without enhanced toxicity.